Exit
In order to receive credit for this activity, you must read the front matter, view the activity, achieve a passing of at least 100% on this post-survey, as well as complete the linked evaluation and application for credit form. Certificates of credit will be emailed to participants who have successfully met these requirements. 

There is no fee to participate in this activity.

Question Title

* 1. What are your specialty & credentials?

Question Title

* 2. What is your community of practice?

Question Title

* 3. 68yo female with metastatic urothelial carcinoma (mUC)
  • Status post treatment with enfortumab vedotin and pembrolizumab
  • On pembrolizumab monotherapy for 12 months
  • FGFR3 and cisplatin eligible
  • Presents with new liver metastases
In your practice, what would you use next?

Question Title

* 4. 74yo female status post treatment with gem/ + cisplatin
  • Avelumab maintenance x12m
  • 🧬No FGFR3 alterations, HER2 IHC 0
  • Presents with new liver mets
What treatment should you use next?

Question Title

* 5. 67 year old male patient with mUC status post treatment with EV+P
  • FGFR3 alteration
  • Treated with erdafitinib in the second-line
  • Serum phosphate 8.0 mg/dL
What should you do next?

EVALUATION FORM

Question Title

* 6. Upon completion of this activity, I am able to:

  Strongly agree Agree Disagree Strongly disagree
Describe efficacy data regarding ICIs and other approved drug classes, including the use of maintenance therapy in mUC.

Question Title

* 7. Please indicate the extent of your agreement with the following statements: 

  Strongly agree Agree Disagree Strongly disagree
The faculty for this activity were effective

Question Title

* 8. Overall, was this activity fair, balanced and free from commercial bias?

Question Title

* 9. If no, please explain:

Question Title

* 10. What percentage of activity content was new to you?

Question Title

* 11. Based on what I learned today, I will improve my practice by incorporating the following (check all that apply):

Question Title

* 12. Based on your experience, which of the following are the primary barriers to implementing changes in practice (check all that apply):

Question Title

* 13. Based on your experience, which of the following are the primary PATIENT-LEVEL barriers to implementing changes in practice in the 2L & subsequent-line settings of mUC (check all that apply):

Question Title

* 14. Based on your experience, which of the following are the primary PROVIDER-LEVEL barriers to implementing changes in practice in the 2L & subsequent-line settings of mUC (check all that apply):

Question Title

* 15. Based on your experience, which of the following are the primary SYSTEM-LEVEL barriers to implementing changes in practice in the 2L & subsequent-line settings of mUC (check all that apply):

Question Title

* 16. For purposes of certification, please complete the following information. *Please note that we will not forward or sell your contact information.*

Question Title

* 17. I certify that I have participated in the continuing education activity entitled, "Tweetorial #2: Second- & Subsequent-line Therapy in mUC" and claim 0.25 AMA PRA Category 1 CreditTM.

Thank you for participating in our activity and completing the necessary paperwork. Your certificate will be emailed to you using the email address provided above. Please allow 4 weeks to receive your certificate. 

For information about the certification of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.
( Privacy & Cookie Notice